Quarterly HIV viral load distributions within each HAART-initiating cohort from January 1, 1996 to June 30, 2010.

<p>Quarterly HIV viral load distributions within each HAART-initiating cohort from January 1, 1996 to June 30, 2010.</p

Figure 2

<p><b>a.</b> Unadjusted and adjusted survival curves from HAART initiation to death by cohort. <b>b.</b> Unadjusted and adjusted survival curves from HAART initiation to death or AIDS (excl. CD4<200) by cohort.</p

Crude and adjusted predictors of time to development of outcomes after initiating HAART using Cox proportional hazards modeling.

<p>Note: Bold hazard ratios (HR) and 95% confidence intervals (CI) are significant at the <i>p</i><0.05 level.</p><p>HAART-Highly Active Antiretroviral Therapy; NHS-US Military HIV Natural History Study; HAVACS-HIV Atlanta VA Cohort Study; AA-African -American/Black; PI-Protease Inhibitor; NNRTI-Non-Nucleoside Reverse Transcriptase Inhibitor.</p>a<p>1993 definition, exclusive of CD4<200.</p

Distributions of variables between NHS and HAVACS.

<p>NHS-US Military HIV Natural History Study; HAVACS-HIV Atlanta VA Cohort Study; HAART-Highly Active Antiretroviral Therapy; IQR-interquartile range; PI-Protease Inhibitor; NNRTI-Non-Nucleoside Reverse Transcriptase Inhibitor; NRTI-Nucleoside Reverse Transcriptase Inhibitor.</p>a<p>Tested for significance with two-sided Wilcoxon rank-sum and chi-square (χ²) tests.</p>b<p>Showed in median units (IQR).</p>c<p>AIDS-defining event utilizes the 1993 CDC definition.</p